ALS News Today

January 17, 2022January 17, 2022

ALS Community Invited to Help Set Research Priorities in US

ALS News Today

The National Institute of Neurological Disorders and Stroke (NINDS) is asking people across the amyotrophic lateral sclerosis (ALS) community to submit their preferences regarding what should be prioritized to accelerate ALS ... Read more

January 14, 2022January 14, 2022

AcuraStem’s AS-202 for ALS Shows Promise in Preclinical Studies

ALS News Today

AcuraStem’s experimental therapy AS-202 significantly reduced neurodegeneration and improved motor function and survival in a mouse model of aggressive amyotrophic lateral sclerosis (ALS) associated with toxic clumps of the TDP-43 ... Read more

January 13, 2022January 13, 2022

Oral Edaravone Under FDA Priority Review, Decision Expected in May

ALS News Today

A decision is expected by May from the U.S. Food and Drug Administration (FDA) on an application seeking approval of an oral formulation of edaravone (MT-1186) — one with a ... Read more

January 12, 2022January 12, 2022

Italian Scientist Using $20K Grant to Research TDP-43 Antibody Therapy

ALS News Today

An Italian scientist was awarded $20,000 for research that may help pave the way for a TDP-43 antibody-based treatment for amyotrophic lateral sclerosis (ALS). The annual Paulo Gontijo Award from ... Read more

January 11, 2022January 11, 2022

Lief Care and AxeALS Partner to Support Patients’ Nutritional Needs

ALS News Today

A Lief Cares initiative, under its partnership with AxeALS, raised nearly $8,000 for the amyotrophic lateral sclerosis (ALS) community and is providing patients with specially formulated nutritional supplements. Lief Cares is the nonprofit ... Read more

January 10, 2022January 10, 2022

Pridopidine Arm of HEALEY ALS Platform Trial Fully Enrolled

ALS News Today

Prilenia Therapeutics announced the completion of patient enrollment in the pridopidine arm of the HEALEY ALS platform trial, the first study to simultaneously test multiple experimental therapies for amyotrophic lateral ... Read more

January 7, 2022January 7, 2022

Amylyx Files for European Approval of AMX0035 in Treating ALS

ALS News Today

Amylyx Pharmaceuticals has filed an application with the European Medicines Agency seeking the approval of its lead candidate AMX0035 as a treatment of amyotrophic lateral sclerosis (ALS), the company announced ... Read more

January 6, 2022January 6, 2022

ALS Patient Posts 1st Tweet Using Stentrode Brain Computer Interface

ALS News Today

A recent tweet by an Australian amyotrophic lateral sclerosis (ALS) patient using an implantable brain computer interface called Stentrode is said to be the first time a message has been ... Read more

January 5, 2022January 5, 2022

Lab Results Support Advancing QRL-201 to Clinical Trial

ALS News Today

An investigational antisense oligonucleotide (ASO) molecule that works by increasing the production of Stathmin-2 protein effectively reversed a number of neurodegenerative processes in lab-grown motor neurons, the cells that are ... Read more

January 4, 2022January 4, 2022

FDA Grants Priority Review to ALS Therapy AMX0035

ALS News Today

The U.S. Food and Drug Administration (FDA) has accepted for review Amylyx Pharmaceuticals‘ application seeking approval of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). The new drug application ... Read more

January 3, 2022January 3, 2022

Top 10 ALS Stories of 2020

ALS News Today, COVID-19 News

ALS News Today brought you daily coverage of key findings, treatment developments, clinical trials, and other important events related to amyotrophic lateral sclerosis (ALS) throughout 2020, a year marked by ... Read more

January 3, 2022January 3, 2022

Top 10 ALS Stories of 2021

ALS News Today

ALS News Today brought you daily coverage of the latest scientific breakthroughs and clinical research related to amyotrophic lateral sclerosis (ALS) throughout 2021. We look forward to continuing to report for ... Read more

December 30, 2021December 30, 2021

NurOwn Dosing Likely to Continue for ALS Patients in Its EAP

ALS News Today

Amyotrophic lateral sclerosis (ALS) patients who completed the expanded access protocol (EAP) for NurOwn may soon be eligible for three additional doses of the cell-based therapy, BrainStorm Cell Therapeutics reported. EAPs, ... Read more

December 29, 2021December 29, 2021

Target ALS, ADDF Team Up to Fund Biomarker Research

ALS News Today

A new partnership between Target ALS and the Alzheimer’s Drug Discovery Foundation (ADDF) will help facilitate biomarker research in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and frontotemporal ... Read more

December 28, 2021December 28, 2021

PRO-ACT Database Wins Healey Center Prize for Innovation in ALS

ALS News Today

The largest collection of amyotrophic lateral sclerosis (ALS) clinical trial data, amassed to help researchers globally find better treatments and potentially a cure for the progressive neurological disorder, was awarded ... Read more